A detailed history of New York State Common Retirement Fund transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 12,046 shares of SAGE stock, worth $65,530. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,046
Previous 21,646 44.35%
Holding current value
$65,530
Previous $235,000 62.98%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$7.02 - $13.08 $67,392 - $125,568
-9,600 Reduced 44.35%
12,046 $87,000
Q2 2024

Jul 31, 2024

SELL
$10.58 - $17.9 $6,739 - $11,402
-637 Reduced 2.86%
21,646 $235,000
Q1 2024

May 07, 2024

SELL
$18.62 - $26.95 $2,569 - $3,719
-138 Reduced 0.62%
22,283 $418,000
Q4 2023

Feb 01, 2024

SELL
$17.1 - $22.26 $4,565 - $5,943
-267 Reduced 1.18%
22,421 $486,000
Q3 2023

Nov 07, 2023

BUY
$16.75 - $48.98 $6,348 - $18,563
379 Added 1.7%
22,688 $467,000
Q2 2023

Aug 07, 2023

SELL
$40.65 - $59.54 $237,477 - $347,832
-5,842 Reduced 20.75%
22,309 $1.05 Million
Q1 2023

May 02, 2023

SELL
$37.27 - $46.57 $406,503 - $507,938
-10,907 Reduced 27.93%
28,151 $1.18 Million
Q4 2022

Jan 30, 2023

BUY
$32.2 - $43.61 $225 - $305
7 Added 0.02%
39,058 $1.49 Million
Q3 2022

Nov 08, 2022

BUY
$32.28 - $43.27 $82,088 - $110,035
2,543 Added 6.97%
39,051 $1.53 Million
Q2 2022

Aug 04, 2022

SELL
$27.52 - $37.99 $1 Million - $1.38 Million
-36,438 Reduced 49.95%
36,508 $1.18 Million
Q1 2022

May 05, 2022

BUY
$30.71 - $45.71 $120,168 - $178,863
3,913 Added 5.67%
72,946 $2.42 Million
Q4 2021

Feb 02, 2022

SELL
$37.06 - $47.11 $85,756 - $109,012
-2,314 Reduced 3.24%
69,033 $2.94 Million
Q3 2021

Nov 02, 2021

SELL
$40.26 - $57.37 $2.04 Million - $2.9 Million
-50,618 Reduced 41.5%
71,347 $3.16 Million
Q2 2021

Aug 02, 2021

SELL
$54.88 - $79.29 $217,928 - $314,860
-3,971 Reduced 3.15%
121,965 $6.93 Million
Q1 2021

May 11, 2021

SELL
$70.65 - $96.76 $805,410 - $1.1 Million
-11,400 Reduced 8.3%
125,936 $9.43 Million
Q4 2020

Feb 08, 2021

BUY
$58.41 - $89.06 $447,829 - $682,823
7,667 Added 5.91%
137,336 $11.9 Million
Q3 2020

Nov 05, 2020

BUY
$41.13 - $62.45 $458,311 - $695,880
11,143 Added 9.4%
129,669 $7.93 Million
Q2 2020

Aug 07, 2020

SELL
$25.95 - $43.15 $1.93 Million - $3.21 Million
-74,353 Reduced 38.55%
118,526 $4.93 Million
Q1 2020

May 06, 2020

SELL
$26.15 - $77.24 $584,007 - $1.73 Million
-22,333 Reduced 10.38%
192,879 $5.54 Million
Q4 2019

Feb 05, 2020

SELL
$60.18 - $154.77 $3.16 Million - $8.13 Million
-52,519 Reduced 19.62%
215,212 $15.5 Million
Q3 2019

Nov 07, 2019

SELL
$140.29 - $189.96 $715,759 - $969,175
-5,102 Reduced 1.87%
267,731 $37.6 Million
Q2 2019

Aug 09, 2019

SELL
$157.85 - $183.09 $1.43 Million - $1.66 Million
-9,080 Reduced 3.22%
272,833 $50 Million
Q1 2019

May 08, 2019

BUY
$89.33 - $163.65 $759,840 - $1.39 Million
8,506 Added 3.11%
281,913 $44.8 Million
Q4 2018

Feb 08, 2019

BUY
$81.94 - $139.71 $535,805 - $913,563
6,539 Added 2.45%
273,407 $26.2 Million
Q3 2018

Nov 07, 2018

SELL
$138.11 - $169.04 $234,787 - $287,368
-1,700 Reduced 0.63%
266,868 $37.7 Million
Q2 2018

Aug 10, 2018

BUY
$140.36 - $175.76 $13.2 Million - $16.5 Million
93,918 Added 53.77%
268,568 $42 Million
Q1 2018

May 10, 2018

BUY
$152.15 - $192.33 $2.18 Million - $2.76 Million
14,355 Added 8.96%
174,650 $28.1 Million
Q4 2017

Feb 13, 2018

BUY
$60.72 - $167.34 $651,586 - $1.8 Million
10,731 Added 7.17%
160,295 $26.4 Million
Q3 2017

Nov 06, 2017

BUY
$61.4 - $88.52 $6.62 Million - $9.54 Million
107,782 Added 257.96%
149,564 $9.32 Million
Q2 2017

Aug 11, 2017

BUY
N/A
41,782
41,782 $3.33 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.